Everlab Raises AU$65M Series A to Expand Preventative Healthcare, June 18

Everlab, a Melbourne healthtech company founded in 2023, raised AU$65 million in a Series A funding round led by Airtree Ventures. The oversubscribed round includes investors Plural, Left Lane Capital, b2venture, and Australian Test cricket captain Pat Cummins. Everlab plans to use the capital to expand globally, starting with the United Kingdom, and strengthen its AI-powered platform that consolidates diagnostics, doctor visits, prescriptions, and continuous care into one place.

What Everlab Does and Why It Matters

Everlab built a digital platform that shifts healthcare from treating illness to preventing it. The app pulls diagnostics, doctor consultations, specialist coordination, prescriptions, and wearable data into one unified record. Most healthcare systems are fragmented, scattering patient information across providers. Everlab aims to give patients a complete health picture over their lifetime rather than disconnected snapshots from separate appointments.

The Funding Round and Investor Backing

The Series A was led by Airtree Ventures, with participation from UK-based Plural and existing backers Left Lane Capital and b2venture. Angel investors include Pat Cummins, captain of the Australian Test cricket team. The company raised AU$10 million in a seed round in July 2025, making this round a substantial step up in funding.

Patient Reach and Platform Scale

Everlab has supported around 20,000 patients to date and processed 21 million biomarker results. More than 25% of members uncovered previously undetected health insights through the platform. The company integrates with over 1,850 healthcare provider locations, 180+ active clinicians, and 30+ wearable devices. It processes more than 200,000 health reports each month.

Expansion Plans and Use of Funds

Everlab plans to use the new capital to strengthen its clinical and technology infrastructure and accelerate global rollout. The United Kingdom is the first market outside Australia and New Zealand. Plural’s participation signals European appetite for preventative healthcare platforms. The company competes with similar startups like Neko Health in Europe and Function Health in the US.

Final Thoughts

Everlab’s AU$65 million Series A reflects strong investor demand for preventative healthcare platforms that consolidate fragmented medical data. The company’s growth from 20,000 patients and AU$10 million seed to this round demonstrates traction in a market shifting from reactive to proactive care.

FAQs

Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes.  Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.